New Therapies Shed Light on RAS-Mutated Pancreatic Cancer Management

Commentary
Video

Shubham Pant, MD, MBBS, highlights an “exciting time” in the treatment of patients with RAS-mutated pancreatic cancer.

In a conversation with CancerNetwork® ahead of his presentation at the 15th Annual Ruesch Center Symposium, Shubham Pant, MD, MBBS, discussed what he hoped colleagues would take away from his session focused on the development of targeted therapies for patients with RAS-mutated pancreatic cancer.

Pant, a professor in the Department of Gastrointestinal Medical Oncology with a joint appointment in the Department of Investigational Cancer Therapeutics (Phase I Center) at The University of Texas MD Anderson Cancer Center, and gastrointestinal cancer editorial advisory board member for ONCOLOGY, contextualized his presentation by highlighting how the RAS mutation was previously considered an “undruggable” target. With the development of novel therapeutic strategies such as pan-RAS inhibitors, Pant stated that the field is now experiencing an “exciting” time.

Based on the ongoing initiatives he will describe in his presentation; Pant ultimately looks for his colleagues to take away a feeling of hope for the future of the field.

Transcript:

I’m excited about the [Ruesch] Symposium this year. About a decade back, we did not have anything to target RAS [mutations], and RAS was called undruggable. However, we first had the KRAS G12C inhibitors, which were mostly in lung and colorectal cancer. Now we have other inhibitors called pan-RAS inhibitors that can target pancreatic cancer. [Approximately] 90% of pancreatic cancer is KRAS-mutated. It’s an exciting time in this field.

What I hope my colleagues take away is that there’s a lot of hope in the future. Pancreatic cancer, normally, has been a tough and devastating disease. Survival has not budged a lot; it has done a bit, but not a lot, only in single digits in the last decades. I truly think this is the moment in which we’re getting newer therapeutics, which can have an impact on our patients’ lives. I hope they take away some hope from this presentation.

Reference

Pant S. Targeting the RAS mutation in pancreatic cancer. Presented at the 15th Annual Ruesch Center Symposium; November 21-23, 2024; Washington, DC.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content